Literature DB >> 15968890

Microcirculatory and clinical effects of serial percutaneous application of carbon dioxide in primary and secondary Raynaud's phenomenon.

J Schmidt1, P Monnet, B Normand, R Fabry.   

Abstract

BACKGROUND: A randomized double-blind monocentric trial was conducted at the spa of Royat, France, in patients with mild Raynaud's phenomenon (one or two attacks a day during the autumn and winter months). Hemodynamic changes were quantified by laser Doppler flow (LDF) and computerized chronothermometric test (CT) during local application of CO2 and compared with the usual clinical parameters. PATIENTS AND METHODS: Patients were randomized to 18 days of CO2 (group 1) or 9 days of air + 9 days of CO2 (group 2). The gas was applied at a constant temperature to previously humidified skin on the forearm. Effects of the active treatment were measured by LDF and continuing benefits by computerized chronothermometric test (CT test). Clinical assessment was made on four occasions (before, in the middle and at the end of treatment, and three months afterwards) on the basis of the number of daily attacks and the duration and severity of the attacks.
RESULTS: LDF showed a significant increase in digital blood flow (+ 41%) and in vasomotion (+ 42%) during CO2 treatment but no change on placebo treatment. CT test showed a comparable response to cold in the two groups during treatment. Three months later, however, warming time was significantly decreased (by 7 minutes: 25%) and warming rate increased (+ 22.4%) in group 1 (intergroup difference: p = 0.02). There was no difference between groups in the weekly number of attacks during treatment periods. In contrast there was a moderate increase in both groups in the winter months. There was no increase in the severity of the attacks nor in their duration.
CONCLUSION: In this clinical trial, LDF evidenced positive effects of percutaneous application of natural CO2 gas on vasomotricity and vasomotion while CT test showed that patients who had received 18 days of CO2 adapted more easily to exposure to cold. Clinical improvement seems to be masked by winter weather conditions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15968890     DOI: 10.1024/0301-1526.34.2.93

Source DB:  PubMed          Journal:  Vasa        ISSN: 0301-1526            Impact factor:   1.961


  10 in total

Review 1.  [Therapeutic management in early disease stages of systemic sclerosis : early diagnosis - early symptoms - early problems].

Authors:  M Frerix; F M P Meier; W Hermann; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

2.  The effect of transcutaneous application of gaseous CO2 on diabetic chronic wound healing-A double-blind randomized clinical trial.

Authors:  Milos Macura; Helena Ban Frangez; Ksenija Cankar; Miha Finžgar; Igor Frangez
Journal:  Int Wound J       Date:  2020-07-07       Impact factor: 3.315

3.  Transcutaneous carbon dioxide application accelerates muscle injury repair in rat models.

Authors:  Shiho Akahane; Yoshitada Sakai; Takeshi Ueha; Hanako Nishimoto; Miho Inoue; Takahiro Niikura; Ryosuke Kuroda
Journal:  Int Orthop       Date:  2017-02-16       Impact factor: 3.075

4.  Transcutaneous Carbon Dioxide Treatment Affects Heart Rate Variability - A Pilot Study.

Authors:  Zita Kreska; Balázs Németh; István Kiss; Iván Péter; Zénó Ajtay; László Hejjel
Journal:  In Vivo       Date:  2018 Sep-Oct       Impact factor: 2.155

5.  The effects of a single carbon dioxide and hot water hand bath on acral perfusion in systemic sclerosis: A randomized, clinical study.

Authors:  Uwe Lange; Stephanie Bogensperger; Ingo H Tarner; Ulf Müller-Ladner
Journal:  J Scleroderma Relat Disord       Date:  2019-01-09

6.  Angiotensin-converting Enzyme Inhibition Improves the Effectiveness of Transcutaneous Carbon Dioxide Treatment.

Authors:  Balazs Nemeth; Istvan Kiss; Timea Jencsik; Ivan Peter; Zita Kreska; Tamas Koszegi; Attila Miseta; Peter Kustan; Imre Boncz; Andrea Laczo; Zeno Ajtay
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

7.  Transcutaneous Carbon Dioxide Treatment Is Capable of Reducing Peripheral Vascular Resistance in Hypertensive Patients.

Authors:  Balázs Németh; István Kiss; Bella Ajtay; Iván Péter; Zita Kreska; Attila Cziráki; Iván G Horváth; Zénó Ajtay
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

8.  A novel system for transcutaneous application of carbon dioxide causing an "artificial Bohr effect" in the human body.

Authors:  Yoshitada Sakai; Masahiko Miwa; Keisuke Oe; Takeshi Ueha; Akihiro Koh; Takahiro Niikura; Takashi Iwakura; Sang Yang Lee; Masaya Tanaka; Masahiro Kurosaka
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

9.  Local Application of Transcutaneous Carbon Dioxide Paste Decreases Inflammation and Accelerates Wound Healing.

Authors:  Rika Amano-Iga; Takumi Hasegawa; Daisuke Takeda; Aki Murakami; Nanae Yatagai; Izumi Saito; Satomi Arimoto; Yasumasa Kakei; Akiko Sakakibara; Masaya Akashi
Journal:  Cureus       Date:  2021-11-12

10.  Facial application of high-concentration carbon dioxide prevents epidermal impairment associated with environmental changes.

Authors:  Katsuyuki Yuki; Sawako Kawano; Shinobu Mori; Takatoshi Murase
Journal:  Clin Cosmet Investig Dermatol       Date:  2019-01-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.